Literature DB >> 24710806

"Not for human consumption": a review of emerging designer drugs.

Megan E Musselman1, Jeremy P Hampton.   

Abstract

Synthetic, or "designer" drugs, are created by manipulating the chemical structures of other psychoactive drugs so that the resulting product is structurally similar but not identical to illegal psychoactive drugs. Originally developed in the 1960s as a way to evade existing drug laws, the use of designer drugs has increased dramatically over the past few years. These drugs are deceptively packaged as "research chemicals," "incense," "bath salts," or "plant food," among other names, with labels that may contain warnings such as "not for human consumption" or "not for sale to minors." The clinical effects of most new designer drugs can be described as either hallucinogenic, stimulant, or opioid-like. They may also have a combination of these effects due to designer side-chain substitutions. The easy accessibility and rapid emergence of new designer drugs have created challenges for health care providers when treating patients presenting with acute toxicity from these substances, many of which can produce significant and/or life-threatening adverse effects. Moreover, the health care provider has no way to verify the contents and/or potency of the agent ingested because it can vary between packages and distributors. Therefore, a thorough knowledge of the available designer drugs, common signs and symptoms of toxicity associated with these agents, and potential effective treatment modalities are essential to appropriately manage these patients.
© 2014 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  2C agents; Bromodragonfly; cannabinoids; cathinones; designer drugs; hallucinogens; phenylethylamines; piperazine derivatives; psychostimulants; synthetic drugs

Mesh:

Substances:

Year:  2014        PMID: 24710806     DOI: 10.1002/phar.1424

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

1.  Investigations of the genotoxic properties of two synthetic cathinones (3-MMC, 4-MEC) which are used as psychoactive drugs.

Authors:  Halh Al-Serori; Franziska Ferk; Verena Angerer; Miroslav Mišík; Armen Nersesyan; Tahereh Setayesh; Volker Auwärter; Elisabeth Haslinger; Wolfgang Huber; Siegfried Knasmüller
Journal:  Toxicol Res (Camb)       Date:  2016-07-22       Impact factor: 3.524

2.  Trends in DMT and other tryptamine use among young adults in the United States.

Authors:  Joseph J Palamar; Austin Le
Journal:  Am J Addict       Date:  2018-10

3.  Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies.

Authors:  Adebisi I Obafemi; Kurt Kleinschmidt; Collin Goto; Drew Fout
Journal:  J Med Toxicol       Date:  2015-12

4.  Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports.

Authors:  Michal Ordak; Aleksandra Zmysłowska; Miłosz Bielski; Daniel Rybak; Maja Tomaszewska; Katarzyna Wyszomierska; Aleksandra Kmiec; Natalia Garlicka; Maria Zalewska; Michal Zalewski; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

5.  A randomized trial of brief assessment interventions for young adults who use drugs in the club scene.

Authors:  Steven P Kurtz; Mance E Buttram; Maria E Pagano; Hilary L Surratt
Journal:  J Subst Abuse Treat       Date:  2017-05-12

Review 6.  Recreational use, analysis and toxicity of tryptamines.

Authors:  Roberta Tittarelli; Giulio Mannocchi; Flaminia Pantano; Francesco Saverio Romolo
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

7.  The Changing Face of Recreational Drug Use.

Authors:  Michael H Baumann
Journal:  Cerebrum       Date:  2016-01-01

Review 8.  When good times go bad: managing 'legal high' complications in the emergency department.

Authors:  Charles R Caffrey; Patrick M Lank
Journal:  Open Access Emerg Med       Date:  2017-12-20

9.  An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA.

Authors:  Joseph A Tyndall; Roy Gerona; Giuliano De Portu; Jordan Trecki; Marie-Carmelle Elie; Judith Lucas; John Slish; Kenneth Rand; Lindsay Bazydlo; Martina Holder; Matthew F Ryan; Paul Myers; Nicole Iovine; Michelle Plourde; Emily Weeks; James R Hanley; Greg Endres; Danielle St Germaine; Paul J Dobrowolski; Michael Schwartz
Journal:  Clin Toxicol (Phila)       Date:  2015-11-10       Impact factor: 3.738

10.  Designer Drugs: A Synthetic Catastrophe.

Authors:  James Fratantonio; Lawrence Andrade; Marcelo Febo
Journal:  J Reward Defic Syndr       Date:  2015-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.